Cisplatin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer

Hopkins, Daniel; Sanchez, Hector; Berwin, Brent; Wilkinson-Ryan, Ivy

doi:10.1016/j.tranon.2021.101217

Cited by 7 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the frequency of moDCs emerged as a strong predictor of PFS and OS in response to anti-PD-1 in another study, which evaluated the immune cell landscape in peripheral blood samples collected from advanced melanoma patients prior to and after 12 weeks of ICB [92]. Other groups described the beneficial role of moDCs for the induction of antitumor immunity following treatment with various chemotherapeutic agents [42,93,94].…”

Section: Phenotypic and Functional Characteristics Of Tumor-infiltrat...mentioning

confidence: 99%

Tumor‐associated human dendritic cell subsets: Phenotype, functional orientation, and clinical relevance

et al. 2022

View full text Add to dashboard Cite

DCs play a pivotal role in orchestrating innate and adaptive antitumor immunity. Activated DCs can produce large amounts of various proinflammatory cytokines, initiate Tcell responses, and exhibit direct cytotoxicity against tumor cells. They also efficiently enhance the antitumoral properties of NK cells and T lymphocytes. Based on these capabilities, immunogenic DCs promote tumor elimination and are associated with improved survival of patients. Furthermore, they can essentially contribute to the clinical efficacy of immunotherapeutic strategies for cancer patients. However, depending on their intrinsic properties and the tumor microenvironment, DCs can be rendered dysfunctional and mediate tolerance by producing immunosuppressive cytokines and activating Treg cells. Such tolerogenic DCs can foster tumor progression and are linked to poor prognosis of patients. Here, we focus on recent studies exploring the phenotype, functional orientation, and clinical relevance of tumor-infiltrating conventional DC1, conventional DC2, plasmacytoid DCs, and monocyte-derived DCs in translational and clinical settings. In addition, recent findings demonstrating the influence of DCs on the efficacy of immunotherapeutic strategies are summarized.

show abstract

Section: Phenotypic and Functional Characteristics Of Tumor-infiltrat...mentioning

confidence: 99%

Tumor‐associated human dendritic cell subsets: Phenotype, functional orientation, and clinical relevance

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Increases of CD20 + and TIA‐1 + immune cell infiltrates were observed in OC tumors with BRCA1 or BRCA2 mutations compared with those without mutations (McAlpine et al 2012), revealing the immunomodulatory role of germline and somatic mutations; (c) Therapeutic strategy. Cisplatin administration elevates immune activity of ascitic monocytes and cytotoxic T‐cells in a murine model of epithelial ovarian cancer (Hopkins et al 2021). On the other hand, treatment with cisplatin or carboplatin enhances the ability of OC cell lines to assist generating tumor‐promoting M2 macrophages (Dijkgraaf et al 2013); (d) Competition between mutant cells and wild‐type cells.…”

Section: The Mechanisms That Determine the Balance Of Tumor‐promoting...mentioning

confidence: 99%

Friend and foe: the regulation network of ascites components in ovarian cancer progression

Geng

Pan

et al. 2022

J. Cell Commun. Signal.

View full text Add to dashboard Cite

The tumor microenvironment (TME) and its complex role in cancer progression have been hotspots of cancer research in recent years. Ascites, which occurs frequently in patients with ovarian cancer especially in advanced stages, represents a unique TME. Malignant ascites contains abundant cellular and acellular components that play important roles in tumorigenesis, growth, metastasis, and chemoresistance of ovarian cancer through complex molecular mechanisms and signaling pathways. As a valuable liquid biopsy sample, ascites fluid is also of great significance for the prognostic analysis of ovarian cancer. The components of ovarian cancer ascites are generally considered to comprise tumor-promoting factors; however, in recent years studies have found that ascites also contains tumor-suppressing factors, raising new perspectives on interactions between ascites and tumors. Malignant ascites directly constitutes the ovarian cancer microenvironment, therefore, the study of its components will aid in the development of new therapeutic strategies. This article reviews the current research on tumor-promoting and tumor-suppressing factors and molecular mechanisms of their actions in ovarian cancer-derived ascites and therapeutic strategies targeting ascites, which may provide references for the development of novel therapeutic targets for ovarian cancer in the future.

show abstract

“…Yigit et al reported undetectable IL-10 levels in MA following NACT; interestingly, they also found minimal IL-10 levels in recurrent patients [ 52 ]. Explorations of IL-10 level change in MA after chemotherapy, using ID8 tumor-bearing mice, indicating a decreasing trend, though statistical significance was not achieved [ 59 ]. Additionally, Park et al disclosed higher IL-10 levels in MA of metastatic gastric cancer (mGC) patients compared to healthy volunteers’ body fluids.…”

Section: Introductionmentioning

confidence: 99%

The complex role of IL-10 in malignant ascites: a review

Huang,

Zou,

Jiang

et al. 2024

Cancer Immunol Immunother

View full text Add to dashboard Cite

The emergence of malignant ascites (MA) indicates poor prognoses in patients with ovarian, gastrointestinal, breast, and pancreatic cancer. Interleukin-10 (IL-10) is a pleiotropic cytokine with immunoregulatory effects in tumor microenvironment. The level of IL-10 in MA varied across cancer types and patients, influencing cancer progression and outcomes. Originating from various immune and cancer cells, IL-10 contributes to complex signaling pathways in MA. Systemic IL-10 administration, although the evidence of its efficacy on MA is limited, still emerges as a promising therapeutic strategy because it can increase CD8+ T cells cytotoxicity and invigorate exhausted CD8+ tumor infiltration lymphocytes (TILs) directly. IL-10 signaling blockade also demonstrates great potential when combined with other immunotherapies in MA treatment. We reviewed the levels, origins, and functions of IL-10 in malignant ascites and overviewed the current IL-10 signaling targeting therapies, aiming to provide insights for MA treatment.

show abstract

Cisplatin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer

Cited by 7 publications

References 26 publications

Tumor‐associated human dendritic cell subsets: Phenotype, functional orientation, and clinical relevance

Tumor‐associated human dendritic cell subsets: Phenotype, functional orientation, and clinical relevance

Friend and foe: the regulation network of ascites components in ovarian cancer progression

The complex role of IL-10 in malignant ascites: a review

Contact Info

Product

Resources

About